mhurhangee/ep-ind-claims huggingface dataset:
A compound of the general formula: or a tautomer, stereoisomer, N -oxide, isotopically-labelled analogue, or a pharmacologically acceptable salt, hydrate or solvate of any of the foregoing, wherein: - R 1, R 2 independently represent hydrogen, an unsubstituted alkyl (C 1 -C 3) group, an alkyl(C 1 -C 3) group substituted with one or more halogen atoms, an alkoxyl(C 1 -C 3) group, or independently a group selected from: cyano, nitro, amino, hydroxyl; - T represents CO, CH 2, substituted alkyl (C 1 -C 2) group, SO, SO 2; - Ar represents unsubstituted aryl (5-6 membered), biaryl (8-10 membered), heteroaryl (5-6 membered), heteroaryl (8-10 membered) having 1-3 heteroatoms independently selected from the group consisting of N, O, S, optionally substituted with one or more substituents selected from alkyl(C 1 -C 3) group, an alkyl(C 1 -C 3) group substituted with one or more halogen atoms, alkoxy(C 1 -C 3) group, alkenyl(C 2 -C 4), halogen, nitro, hydroxyl, cyano, amino, alkylamino, carboxamide; - R 3 represents substituent selected from the group of cyclic or linear substituted or not substituted amines consisting of structures XV-XVIII: wherein: - A represents NH, O, CH 2, NR 5; - B represents NH, O, NR 4; - R 4 represents hydrogen atom or alkyl(C 1 -C 3) group; - R 5 represents alkyl(C 1 -C 3) group or benzyl; - R 6 represents alkyl(C 1 -C 3) group; - n is selected from 0, 1, 2; - m is selected from 0, 1, 2; - I is selected from 1 and 2. - R 1, R 2 independently represent hydrogen, an unsubstituted alkyl (C 1 -C 3) group, an alkyl(C 1 -C 3) group substituted with one or more halogen atoms, an alkoxyl(C 1 -C 3) group, or independently a group selected from: cyano, nitro, amino, hydroxyl; - T represents CO, CH 2, substituted alkyl (C 1 -C 2) group, SO, SO 2; - Ar represents unsubstituted aryl (5-6 membered), biaryl (8-10 membered), heteroaryl (5-6 membered), heteroaryl (8-10 membered) having 1-3 heteroatoms independently selected from the group consisting of N, O, S, optionally substituted with one or more substituents selected from alkyl(C 1 -C 3) group, an alkyl(C 1 -C 3) group substituted with one or more halogen atoms, alkoxy(C 1 -C 3) group, alkenyl(C 2 -C 4), halogen, nitro, hydroxyl, cyano, amino, alkylamino, carboxamide; - R 3 represents substituent selected from the group of cyclic or linear substituted or not substituted amines consisting of structures XV-XVIII: - A represents NH, O, CH 2, NR 5; - B represents NH, O, NR 4; - R 4 represents hydrogen atom or alkyl(C 1 -C 3) group; - R 5 represents alkyl(C 1 -C 3) group or benzyl; - R 6 represents alkyl(C 1 -C 3) group; - n is selected from 0, 1, 2; - m is selected from 0, 1, 2; - I is selected from 1 and 2.
A rotational atherectomy device for removing a stenotic tissue from a vessel of a patient, the device comprising a rotatable, flexible, hollow drive shaft having a longitudinal axis (W-W) and an open distal end, the drive shaft comprising a fluid impermeable wall, an abrasive element mounted to the drive shaft proximal to and spaced away from its distal end, the fluid impermeable wall being formed from a torque transmitting coil and at least one fluid impermeable membrane which define a lumen for the antegrade flow of pressurized fluid through the drive shaft and into a distal fluid inflatable support element to inflate said fluid inflatable support element, the distal fluid inflatable support element being located at the distal end of the drive shaft and having an outer wall comprising an outflow opening having an axis (K-K) located such that the outflow opening forms an acute angle (α) of at least sixty degrees with respect to the longitudinal axis (W-W) of the drive shaft and faces an inner surface of a treated vessel during rotation of the drive shaft so that a flow of fluid out of said opening forms a layer of fluid between the outer wall of the fluid inflatable distal support element and a wall of the treated vessel, said layer of fluid forming a fluid bearing between the outer wall of the rotating fluid inflated distal support element and the wall of the treated vessel.
An integrated antenna element comprising: a compact printed board comprising a top PCB and a bottom PCB in a laminate structure; and at least two radiating elements integrated with the compact printed board, each radiating element comprising a radiating surface unit and a layered-balun, wherein each layered-balun comprises a first balun set on the top PCB and a second balun set on the bottom PCB; the first balun and the second balun of each layered-balun and the radiating surface unit of each radiating element are spaced from each other along a thickness of the compact printed board with the respective radiating surface unit being sandwiched between the first balun 31 and the second balun 32; each radiating surface unit comprises a first pair of radiating arms and a second pair of radiating arms; and for each radiating element, the first balun is coupled to the first pair of radiating arms to form a first dipole of a first polarization, and the second balun is coupled to the second pair of radiating arms to form a second dipole of a second polarization, the second polarization being orthogonal to the first polarization. a compact printed board comprising a top PCB and a bottom PCB in a laminate structure; and at least two radiating elements integrated with the compact printed board, each radiating element comprising a radiating surface unit and a layered-balun, wherein each layered-balun comprises a first balun set on the top PCB and a second balun set on the bottom PCB; the first balun and the second balun of each layered-balun and the radiating surface unit of each radiating element are spaced from each other along a thickness of the compact printed board with the respective radiating surface unit being sandwiched between the first balun 31 and the second balun 32; each radiating surface unit comprises a first pair of radiating arms and a second pair of radiating arms; and for each radiating element, the first balun is coupled to the first pair of radiating arms to form a first dipole of a first polarization, and the second balun is coupled to the second pair of radiating arms to form a second dipole of a second polarization, the second polarization being orthogonal to the first polarization.
An antimicrobial mouth rinse composition comprising: a. polyol solvent selected from the group consisting of polyhydric alkanes, polyhydric alkane esters, polyalkene glycols, and mixtures thereof; b. sugar alcohol solvent selected from the group consisting of sorbitol, xylitol, mannitol, maltitol, inositol, allitol, altriol, dulcitol, galactitol, glucitol, hexitol, iditol, pentitol, ribitol, erythritol, and mixtures thereof, wherein the total amount of sugar alcohol solvent does not exceed 17% w/v of the composition; c. alkyl sulfate surfactant, and optionally an additional surfactant selected from the group consisting of anionic surfactants, nonionic surfactants, amphoteric surfactants and mixtures thereof; d. buffer system selected from the group consisting of sodium benzoate and benzoic acid in amounts of from 0.01% to 1.0% w/v of the composition; and sodium citrate and citric acid in amounts of from 0.001% to 1.0% w/v of the composition; and phosphoric acid and sodium/potassium phosphate in amounts from 0.01% to 1.0% by weight of the composition; e. one or more antimicrobial essential oils; and f. water; wherein said composition is free of C 2 -C 4 monohydric alcohols. a. polyol solvent selected from the group consisting of polyhydric alkanes, polyhydric alkane esters, polyalkene glycols, and mixtures thereof; b. sugar alcohol solvent selected from the group consisting of sorbitol, xylitol, mannitol, maltitol, inositol, allitol, altriol, dulcitol, galactitol, glucitol, hexitol, iditol, pentitol, ribitol, erythritol, and mixtures thereof, wherein the total amount of sugar alcohol solvent does not exceed 17% w/v of the composition; c. alkyl sulfate surfactant, and optionally an additional surfactant selected from the group consisting of anionic surfactants, nonionic surfactants, amphoteric surfactants and mixtures thereof; d. buffer system selected from the group consisting of sodium benzoate and benzoic acid in amounts of from 0.01% to 1.0% w/v of the composition; and sodium citrate and citric acid in amounts of from 0.001% to 1.0% w/v of the composition; and phosphoric acid and sodium/potassium phosphate in amounts from 0.01% to 1.0% by weight of the composition; e. one or more antimicrobial essential oils; and f. water;
Optical sensor arrangement, comprising: - an optical sensor comprising an integrated circuit arranged in or on a substrate, wherein the substrate comprises a main surface divided into a first surface area and a second surface area, - at least one optically active sensor component arranged on or in the substrate of the first surface area, wherein the optically active sensor component is arranged for emitting and/or detecting light of a desired wavelength range, - optically inactive sensor circuitry arranged on or in the substrate of the second surface area, - a display panel comprising an active display area and a non-active display area, wherein the non-active display area comprises a material which is optically transparent in the desired wavelength range and at least partly frames the active display area; the sensor arrangement being characterised in that - the optical sensor and the display panel are stacked such that, with respect to a main direction of display emission defined by a surface normal of the display panel and perpendicular to the active display area, in a top view along the direction defined by the surface normal, the optically inactive sensor circuitry component is arranged below the active display area and the optically active sensor component is arranged below the non-active display area. - an optical sensor comprising an integrated circuit arranged in or on a substrate, wherein the substrate comprises a main surface divided into a first surface area and a second surface area, - at least one optically active sensor component arranged on or in the substrate of the first surface area, wherein the optically active sensor component is arranged for emitting and/or detecting light of a desired wavelength range, - optically inactive sensor circuitry arranged on or in the substrate of the second surface area, - a display panel comprising an active display area and a non-active display area, wherein the non-active display area comprises a material which is optically transparent in the desired wavelength range and at least partly frames the active display area; the sensor arrangement being characterised in that - the optical sensor and the display panel are stacked such that, with respect to a main direction of display emission defined by a surface normal of the display panel and perpendicular to the active display area, in a top view along the direction defined by the surface normal, the optically inactive sensor circuitry component is arranged below the active display area and the optically active sensor component is arranged below the non-active display area.
A diagnostic method for determining a suitable treatment regimen for a subject suffering from or having a pre-disposition to subclinical Cushing's syndrome, said method comprising: i) determining the level of cortisol in an isolated sample from the subject and comparing said level to control cortisol levels as a measure of subclinical Cushing's syndrome; ii) providing an effective amount of metyrapone in said subject; and iii) analysing the improvement of hypertension and/or glucose metabolism and/or osteoporosis in said subject as a measure of the response of the subject to the administration of metyrapone to determine an improvement or not of the subject's condition and define a suitable treatment regimen. i) determining the level of cortisol in an isolated sample from the subject and comparing said level to control cortisol levels as a measure of subclinical Cushing's syndrome; ii) providing an effective amount of metyrapone in said subject; and iii) analysing the improvement of hypertension and/or glucose metabolism and/or osteoporosis in said subject as a measure of the response of the subject to the administration of metyrapone to determine an improvement or not of the subject's condition and define a suitable treatment regimen.
A balloon catheter, comprising: a shaft configured for insertion into a heart of a patient; a balloon made of an expandable membrane, which is fitted at a distal end of the shaft; a flexible substrate, which is disposed on the membrane; one or more electrodes, which are disposed over the flexible substrate and have a fishbone configuration; and one or more radiopaque flags, which are coupled to the expandable membrane, the one or more radiopaque flags include a serpentine pattern so that the radiopaque flags fold in conformance with flexible substrate as the expandable membrane is collapsed into a compressed or folded configuration. a shaft configured for insertion into a heart of a patient; a balloon made of an expandable membrane, which is fitted at a distal end of the shaft; a flexible substrate, which is disposed on the membrane; one or more electrodes, which are disposed over the flexible substrate and have a fishbone configuration; and one or more radiopaque flags, which are coupled to the expandable membrane, the one or more radiopaque flags include a serpentine pattern so that the radiopaque flags fold in conformance with flexible substrate as the expandable membrane is collapsed into a compressed or folded configuration.
A cylindrical battery cell, which includes a first electrode terminal and a second electrode terminal formed at a top outer circumference and a center portion of the cylindrical battery cell and having different polarities, the cylindrical battery cell comprising: an electrode assembly in which a positive electrode, a negative electrode and a separator interposed between the positive electrode and the negative electrode are wound; a battery case configured to include the electrode assembly therein in a state of being impregnated with an electrolytic solution; a cap assembly mounted to an open top end of the battery case; characterised in that the cylindrical battery cell further comprises, a connection cap including a cap housing loaded on the battery case and the cap assembly and having an insulating material, and a first connection plate and a second connection plate placed on the cap housing and electrically connected to the first electrode terminal and the second electrode terminal, respectively. an electrode assembly in which a positive electrode, a negative electrode and a separator interposed between the positive electrode and the negative electrode are wound; a battery case configured to include the electrode assembly therein in a state of being impregnated with an electrolytic solution; a cap assembly mounted to an open top end of the battery case; characterised in that the cylindrical battery cell further comprises, a connection cap including a cap housing loaded on the battery case and the cap assembly and having an insulating material, and a first connection plate and a second connection plate placed on the cap housing and electrically connected to the first electrode terminal and the second electrode terminal, respectively.
A compound based on the structure of kahalalide F of formula 1, designated KF which is [Orn 11]-KF, wherein the amino acid indicated between brackets is the modification introduced in the structure of kahalalide F; or a pharmaceutical acceptable salt thereof.
A method of manufacturing a cell plate structure for a solid oxide electrolyte type fuel cell, comprising: forming a lower electrode layer; forming an upper electrode layer the upper electrode layer being provided in opposition to the lower electrode layer; forming a solid electrolyte layer, which is provided between the lower electrode layer and the upper electrode layer; allowing a substance (10 to 18) to be contained in at least one of the lower electrode layer and the upper electrode layer; and executing a post-treatment by removing the substance, contained in the at least of the lower electrode layer and the upper electrode layer during formation thereof, after the at least one of the lower electrode layer and the upper electrode layer has been formed, to make the at least one of the lower electrode layer and the upper electrode layer porous, characterized in that the substance (10 to 18) contained in the at least one of the lower electrode layer and the upper electrode layer during formation thereof is composed of a material to be gasified by a plasma treatment, and the post-treatment includes a plasma treatment. forming a lower electrode layer; forming an upper electrode layer the upper electrode layer being provided in opposition to the lower electrode layer; forming a solid electrolyte layer, which is provided between the lower electrode layer and the upper electrode layer; allowing a substance (10 to 18) to be contained in at least one of the lower electrode layer and the upper electrode layer; and executing a post-treatment by removing the substance, contained in the at least of the lower electrode layer and the upper electrode layer during formation thereof, after the at least one of the lower electrode layer and the upper electrode layer has been formed, to make the at least one of the lower electrode layer and the upper electrode layer porous, characterized in that the substance (10 to 18) contained in the at least one of the lower electrode layer and the upper electrode layer during formation thereof is composed of a material to be gasified by a plasma treatment, and the post-treatment includes a plasma treatment.
A cyanobenzothiazole compound of formula I: Wherein Z is H, F, Cl, Br, I, CN, amino, alkylamino, dialkylamino, alkyl ester, carboxy, carboxylic acid salt, alkyl amide, phosphate, alkyl phosphonate, sulfate, alkyl sulfonate, nitro, or (C 1 -C 10)alkyl optionally unsaturated and optionally substituted with amino, hydroxy, oxo (=O), nitro, thiol, or halo; each R 1 is independently H, F, Cl, Br, I, CN, (C 1 -C 6)alkyl, (C 1 -C 6)alkoxy, or (C 1 -C 6)alkylthio, wherein each alkyl, alkoxy, or alkylthio is optionally substituted with F, Cl, Br, I, amino, alkenyl, alkynyl, cycloalkyl, aryl, alkyl sulfonate, or CO 2 M wherein M is H, an organic cation, or an inorganic cation; n is 0, 1, or 2; Y is a linking group comprising (C 1 -C 16)alkyl optionally substituted with one or more halo, oxo (=O), (C 1 -C 6)alkyl, or (C 1 -C 6)alkoxy, and optionally interrupted with one or more N(R 1), O, S, or -N-C(=O)- groups; and X is a solid support. Z is H, F, Cl, Br, I, CN, amino, alkylamino, dialkylamino, alkyl ester, carboxy, carboxylic acid salt, alkyl amide, phosphate, alkyl phosphonate, sulfate, alkyl sulfonate, nitro, or (C 1 -C 10)alkyl optionally unsaturated and optionally substituted with amino, hydroxy, oxo (=O), nitro, thiol, or halo; each R 1 is independently H, F, Cl, Br, I, CN, (C 1 -C 6)alkyl, (C 1 -C 6)alkoxy, or (C 1 -C 6)alkylthio, wherein each alkyl, alkoxy, or alkylthio is optionally substituted with F, Cl, Br, I, amino, alkenyl, alkynyl, cycloalkyl, aryl, alkyl sulfonate, or CO 2 M wherein M is H, an organic cation, or an inorganic cation; n is 0, 1, or 2; Y is a linking group comprising (C 1 -C 16)alkyl optionally substituted with one or more halo, oxo (=O), (C 1 -C 6)alkyl, or (C 1 -C 6)alkoxy, and optionally interrupted with one or more N(R 1), O, S, or -N-C(=O)- groups; and X is a solid support.
A closed loop system for sequentially activating a plurality of distinct muscles in a patient's body, said system comprising a plurality of discrete implantable devices including: a plurality of implantable stimulator devices each device being suitable for placement proximate to a muscle for stimulating the muscle; and one or more implantable sensor devices; wherein each of said plurality of implantable devices has a unique predefined identification address; the system further comprising a system control unit having communication / control circuitry (304, 306, 308, 310, 314) configured for wirelessly transmitting command signals to said plurality of implantable stimulator devices in order to instruct the plurality of implantable stimulator devices to energize, to periodically interrogate the one or more sensors, and to adjust the command signals transmitted to one or more of the stimulators accordingly; and characterized in that each of said plurality of implantable devices comprise a sealed elongate housing that is suitable for injection into the patient's body, each housing having an axial dimension of less than 60 mm and a lateral dimension of less than 6 mm and in that said system control unit is configured to sequentially energize the plurality of stimulator devices with a time delay between energizing each stimulator device. a plurality of implantable stimulator devices each device being suitable for placement proximate to a muscle for stimulating the muscle; and one or more implantable sensor devices; wherein each of said plurality of implantable devices has a unique predefined identification address; the system further comprising a system control unit having communication / control circuitry (304, 306, 308, 310, 314) configured for wirelessly transmitting command signals to said plurality of implantable stimulator devices in order to instruct the plurality of implantable stimulator devices to energize, to periodically interrogate the one or more sensors, and to adjust the command signals transmitted to one or more of the stimulators accordingly; and characterized in that each of said plurality of implantable devices comprise a sealed elongate housing that is suitable for injection into the patient's body, each housing having an axial dimension of less than 60 mm and a lateral dimension of less than 6 mm and in that said system control unit is configured to sequentially energize the plurality of stimulator devices with a time delay between energizing each stimulator device.
A magnetic memory cell (30; 60; 70; 80; 90; 100), comprising: a stack (31; 61; 71; 81; 91; 101) including a magnetic layer section between a conductive layer section and a section of the layer that is different from the conductive layer, the magnetic layer having a magnetization perpendicular to the plane of the layers; a metallization section (42; 62; 72; 82; 92; 102) on which the stack is placed; and first, second, third and fourth metallization arms (44D to 44G), each arm having a median axis (45D to 45G), wherein, for each arm, a current flowing towards the stack in the direction of the median axis sees that section of the stack which is closest to the arm mostly on its left for the first and second arms (44E, 44G), and mostly on its right for the third and fourth arms (44D, 44F). a stack (31; 61; 71; 81; 91; 101) including a magnetic layer section between a conductive layer section and a section of the layer that is different from the conductive layer, the magnetic layer having a magnetization perpendicular to the plane of the layers; a metallization section (42; 62; 72; 82; 92; 102) on which the stack is placed; and first, second, third and fourth metallization arms (44D to 44G), each arm having a median axis (45D to 45G), wherein, for each arm, a current flowing towards the stack in the direction of the median axis sees that section of the stack which is closest to the arm mostly on its left for the first and second arms (44E, 44G), and mostly on its right for the third and fourth arms (44D, 44F).